Lower Urinary Tract Symptoms With New Hematuria

Learning objectives#

• Separate symptom burden from obstruction, infection, medicine effects, neurologic dysfunction, kidney disease, and urinary tract malignancy.
• Connect urinalysis, culture, kidney function, post-void residual measurement, imaging, and cystoscopy to distinct clinical decisions.
• Recognize when chronic incomplete emptying requires same-day bladder protection rather than routine symptom treatment alone.
• Compare behavioral, medicine, catheter, and procedural options while addressing falls, sexual effects, eye surgery, anticoagulation, and kidney constraints.
• Build a closed-loop plan for hematuria results, catheter care, urology referral, and recurrence.

Initial presentation#

A 72-year-old man schedules a primary-care visit for gradually worsening urinary symptoms: for about nine months, his stream has become slower, he waits before urine starts, and he often returns to the bathroom within twenty minutes because he still feels full. He now wakes three or four times most nights. The symptoms interrupt sleep and make a two-hour bus trip difficult, but he has continued to urinate every day.

Three days before the visit, the toilet water appeared red at the end of urination. The next morning he passed pink urine and one small clot. There was no flank pain, burning, fever, or recent urinary procedure. The urine has since looked yellow. He almost cancelled because a friend told him that his anticoagulant was the obvious cause.

His history includes atrial fibrillation, hypertension, chronic knee pain, and a fall without injury six months ago. He takes an oral anticoagulant, two blood-pressure medicines, and an over-the-counter sedating antihistamine on many nights. He started the antihistamine when nocturia disrupted sleep. He has cataract surgery planned in six weeks. He smoked for twenty years and stopped more than two decades ago. He has never had pelvic radiation, a urinary catheter, kidney stones, or urologic surgery. No family member is known to have bladder or kidney cancer.

He reports no weight loss, night sweats, bone pain, new leg weakness, saddle sensory change, loss of bowel control, constipation severe enough to obstruct urination, penile discharge, scrotal symptoms, or recent sexual infection concern. A private sexual history is obtained without assumptions. He wants symptom relief but values remaining steady on his feet, preserving sexual function, and avoiding an unnecessary procedure; he lives alone and would need transportation for a distant urology appointment.

Blood pressure is 128/72 mm Hg while seated and 112/68 mm Hg after standing, with brief lightheadedness. He is afebrile and appears well. The abdomen is soft, but a smooth fullness is palpable above the pubic bone after he voids. There is no costovertebral-angle tenderness. External genital examination shows no lesion or urethral discharge. Rectal examination finds a symmetrically enlarged, smooth prostate without marked tenderness or a hard nodule. Lower-limb strength, reflexes, perineal sensation, and gait are unchanged from baseline.

A symptom questionnaire confirms substantial voiding and storage burden. The score measures impact and later response; it does not diagnose the cause. A bedside bladder scan after a witnessed void estimates 580 mL remaining. Because technique, timing, and anatomy can affect one measurement, the clinician repeats the scan after another attempt. It remains above 500 mL.

Problem representation#

This is an older adult with months of bothersome mixed lower urinary tract symptoms, repeatedly high post-void residual volume, a palpable post-void bladder, orthostatic symptoms, a medicine that may impair emptying, and two episodes of painless visible hematuria with a small clot. He takes an anticoagulant and has a prior smoking history. He currently has no fever, severe pain, complete inability to void, or focal neurologic deficit.

Prostate enlargement may contribute to bladder outlet obstruction, but it does not unify the case safely. The immediate questions are whether retained urine is threatening the kidneys or bladder, whether a reversible medicine or neurologic process contributes, and whether the visible blood signals a urinary tract lesion. Anticoagulation may amplify bleeding, yet it cannot identify where the bleeding began.

Prioritized differential#

1. Bladder outlet obstruction associated with benign prostate enlargement#

Reasoning for: Progressive hesitancy, weak stream, and the incomplete-emptying sensation fit obstruction related to prostate enlargement. So do nocturia, a smooth enlarged prostate, and a reproducibly high residual. Age and symptom trajectory support this branch.

Reasoning against or still uncertain: Symptoms do not prove histologic benign prostatic hyperplasia or explain bladder contractility. Prostate size correlates imperfectly with obstruction. A urethral stricture, bladder-neck lesion, medicine effect, or underactive bladder could create the same pattern. Visible hematuria cannot be assigned to the prostate before other causes are assessed.

2. Urothelial or renal malignancy#

Reasoning for: Painless visible hematuria, a clot, older age, and past smoking make a bladder or upper-tract tumor a serious possibility. A tumor near the bladder outlet could contribute to both bleeding and emptying difficulty.

Why it cannot be missed: Bleeding may be intermittent, and a normal interval urinalysis or symptom improvement would not erase the history. Imaging evaluates much of the upper tract, while cystoscopy directly evaluates the urethra and bladder. One does not fully replace the other.

3. Urinary infection or prostatitis#

Infection can cause blood, urgency, frequency, and impaired emptying. Fever, dysuria, and perineal pain would support it. So would pyuria, bacteriuria, and a positive culture. Their absence lowers the probability but does not make culture unnecessary. Antibiotics should not become a diagnostic trial in a stable person with no supporting evidence.

4. Stone disease#

A ureteral, kidney, bladder, or urethral stone can bleed and sometimes obstruct, but the absence of colicky flank pain does not exclude a stone, and a bladder stone can accompany chronic residual urine. Imaging choice must consider which part of the tract and which alternative diagnoses need evaluation.

5. Medicine-related or functional incomplete emptying#

Sedating antihistamines with anticholinergic effects can worsen retention, while some decongestants increase outlet tone. Opioids, several psychiatric medicines, and other anticholinergic drugs also matter. Diabetes, long-standing bladder overdistention, pelvic surgery, and neurologic disease may reduce detrusor contraction. Medicine review is a treatment opportunity, not permission to stop the hematuria evaluation.

6. Kidney parenchymal disease#

Glomerular disease becomes more likely with proteinuria, dysmorphic red cells, or cellular casts. It becomes more likely with edema, hypertension, or a decline in filtration not explained by obstruction. The visible clot favors a lower urinary source, but mixed processes remain possible. Nephrology and urology pathways can proceed together when findings support both.

7. Acute clot retention, obstructive kidney injury, or cauda equina syndrome#

These are current safety branches rather than the most likely single diagnosis. Inability to pass urine, a painful distended bladder, ongoing heavy bleeding with clots, reduced urine output, rising creatinine, hydronephrosis, fever, hypotension, new bilateral weakness, saddle numbness, or bowel dysfunction would accelerate emergency decompression and cause-specific evaluation.

Focused history and examination#

The clinician dates each urinary change. The questions cover frequency, urgency, and nocturia. They cover hesitancy, intermittency, and straining. They cover weak stream, dribbling, incontinence, pain, and the sense of emptying. A three-day bladder diary can separate high nighttime urine production from a small functional bladder capacity, sleep disruption, diuretic timing, and outlet symptoms. Fluid restriction is not prescribed reflexively because dehydration, falls, kidney disease, and constipation can worsen.

The blood history records whether urine was pink, red, or brown; whether blood appeared throughout or only during part of the stream; clots; recurrence; pain; exercise; trauma; infection symptoms; stone history; and recent instrumentation. The clinician asks about tobacco, occupational chemicals, and pelvic radiation. The questions cover cyclophosphamide, prior cancer, and family history. None is treated as a pass-fail gate.

Every prescription, supplement, and nonprescription product is reviewed. The patient is asked specifically about cold remedies, antihistamines, and sleep products. The questions cover bladder medicines, opioids, and medicines that lower blood pressure. Anticoagulant indication, adherence, and last dose are documented. So are kidney function, bleeding elsewhere, and stroke risk. The anticoagulant is not stopped casually.

Focused examination includes repeated vital signs, orthostatic symptoms, and hydration. It includes abdominal and flank examination, external genital inspection, a proportionate rectal examination, and a neurologic screen. A hard or asymmetric prostate finding would change the prostate-cancer branch but is neither necessary nor sufficient for cancer. Distal weakness, altered reflexes, perineal sensory loss, or abnormal anal tone would redirect the patient urgently toward a spinal pathway.

The clinician asks how symptoms affect sleep, work, and travel. The same question covers intimacy, toileting, and mental health. Privacy is offered for urinary and sexual questions. Mobility, hand dexterity, and vision are clinical data because they determine whether a plan is feasible. So are bathroom access, medicine cost, transportation, and the ability to manage a catheter.

Diagnostic strategy#

Answer the bladder and kidney safety questions first#

Urinalysis with microscopy distinguishes red cells from pigment and looks for pyuria, protein, glucose, and casts. Urine culture is obtained before antibiotics because infection is plausible but not established. Complete blood count assesses anemia or systemic infection. Serum creatinine, electrolytes, and comparison with prior values test for obstructive or other kidney injury.

Post-void residual volume is repeated under defined conditions. One number does not reveal whether the cause is outlet obstruction or weak bladder contraction. A kidney and bladder ultrasound assesses hydronephrosis, stones, bladder distention, wall change, and selected masses without contrast or ionizing radiation; uroflowmetry and pressure-flow studies become useful when the diagnosis remains uncertain or a procedural decision depends on distinguishing obstruction from impaired contraction. They are not required before addressing an unsafe bladder.

Investigate the bleeding as its own problem#

Visible hematuria warrants prompt urologic assessment. The exact upper-tract imaging plan is individualized. Computed-tomography urography can evaluate renal and urothelial causes but uses ionizing radiation and iodinated contrast. Kidney function, contrast reaction history, and pregnancy possibility when relevant affect the choice. So does the diagnostic question. Together they decide whether ultrasound, magnetic-resonance urography, or another protocol is safer. ACR and urologic guidance do not make every hematuria presentation identical.

Cystoscopy is needed when direct inspection of the bladder and urethra will change management. A reassuring scan cannot reliably exclude every small bladder lesion. Conversely, cystoscopy does not evaluate renal parenchyma and the entire upper tract, and urine cytology or tumor-marker tests may help in selected risk settings, but they do not replace standard anatomic evaluation and can produce false reassurance or false-positive cascades.

Keep prostate questions separate#

Prostate-specific antigen testing is a shared decision informed by age, health, and preferences. Prior testing, prostate size, and whether the result would change care inform it too. Retention, infection, recent instrumentation, and prostate medicines can affect interpretation. A prostate marker is not a test for the source of visible hematuria. Routine urine culture, cystoscopy, imaging, and kidney assessment each answer different questions.

Progressive results and interpretation#

Urinalysis contains more than 50 red blood cells per high-power field, with no substantial protein, white-cell excess, or cellular casts. Culture shows no growth. Hemoglobin is normal. Creatinine is 1.5 mg/dL compared with 1.0 mg/dL one year earlier. The result could reflect obstruction, another kidney process, or a temporary change, but it cannot be dismissed.

Ultrasound confirms a distended bladder after voiding, an estimated residual of 610 mL, and mild dilation of both kidney collecting systems. No large stone is seen. The combination of persistent residual urine, a creatinine change, and upper-tract dilation turns symptom management into bladder and kidney protection. The patient is stable, comfortable, and still passing urine, so the primary-care clinician speaks directly with urology rather than sending an unowned electronic referral.

Urology arranges same-day catheter drainage in a monitored setting, accounting for the visible bleeding and anticoagulation. The team watches urine output, blood pressure, electrolytes, and kidney function because substantial decompression can be followed by high urine output and volume disturbance. Exact catheter technique and a voiding trial are governed by the local protocol. The sedating antihistamine is stopped with safer sleep support discussed.

Kidney function begins to improve. An alpha-adrenergic blocker is considered to reduce outlet resistance, but his orthostatic symptoms, fall history, blood-pressure medicines, and upcoming cataract operation require a specific safety conversation. He is told to rise slowly, report syncope, and inform the eye surgeon about current or prior use. No exact product or dose is supplied in this educational case.

Upper-tract imaging shows no kidney mass, stone, or upper-tract filling defect, but it does show an enlarged prostate and bladder-wall trabeculation, findings compatible with long-standing outlet stress but not proof that the prostate caused the bleeding. Cystoscopy identifies a small papillary bladder lesion away from the outlet. Urology arranges endoscopic removal and pathology. The case therefore contains two clinically important processes: probable prostate-related outlet obstruction and a separate bladder lesion that explains why hematuria could not be assigned to anticoagulation or benign enlargement.

Pathology later confirms a non-muscle-invasive urothelial tumor. Grade, depth, completeness of removal, and recurrence risk determine the specialist surveillance and treatment plan, and those details are intentionally left to the final pathology and urologic oncology review rather than inferred from appearance.

Management plan#

Protect bladder and kidney function#

The immediate management goal is reliable drainage while renal function and upper-tract dilation are reassessed: catheter options include short-term urethral drainage, suprapubic drainage in selected circumstances, or intermittent catheterization when the person can perform it safely and the anatomy permits. Infection, urethral trauma, and blockage are harms that require education and an accountable contact. So are bleeding, discomfort, and reduced mobility. A catheter is a bridge, not a diagnosis.

If kidney function fails to improve, drainage remains incomplete, fever develops, or hydronephrosis persists, the team reopens the differential for upper-tract obstruction, high-pressure retention, bladder dysfunction, infection, and intrinsic kidney disease. Nephrology is added when renal findings cannot be explained by the outlet pathway.

Treat bothersome symptoms without ignoring constraints#

Behavioral measures include reviewing fluid timing rather than severe restriction, moderating evening alcohol or caffeine when relevant, treating constipation, planning bathroom access, and avoiding medicines that worsen emptying. A symptom score and bladder diary provide measurable outcomes.

Alpha blockers may improve symptoms relatively quickly but can cause dizziness, low blood pressure, and ejaculatory effects; cataract-surgery planning matters because this medicine class has an association with intraoperative iris behavior. Five-alpha-reductase inhibitors may reduce progression in appropriately enlarged prostates, but benefit develops over months and sexual adverse effects, breast symptoms, mood concerns, and altered prostate-marker interpretation require discussion. Combination therapy adds potential benefit and burden.

Antimuscarinic medicines and other storage-symptom therapies require caution when residual urine is high or emptying is unsafe. Treating urgency while worsening retention would be a foreseeable harm. Medicines are reviewed after a defined interval for symptom change, standing blood pressure, residual volume, adverse effects, and adherence.

Procedural choices depend on prostate size and shape, obstruction evidence, bladder function, kidney effects, bleeding, stone or infection history, anesthesia risk, anticoagulation, durability, retreatment risk, and preferences about ejaculation and recovery. Persistent retention, kidney impairment, recurrent infection or stones, refractory bleeding truly attributable to the prostate, or failed medicine management can strengthen the case for an outlet procedure. The bladder tumor pathway is completed before anyone labels bleeding as prostatic.

Coordinate anticoagulation and tumor care#

The anticoagulant protects against embolic stroke. Continuing it can increase procedural bleeding, while interruption can increase thromboembolic risk. Urology, the prescribing clinician, and anesthesia create a documented peri-procedural plan. They use the actual procedure, kidney function, bleeding severity, and indication. The patient is not told to hold or restart it from a generic handout.

The bladder lesion is removed and risk-classified through urology. Surveillance schedule, intravesical treatment, and repeat procedures depend on exact pathology and response. Primary care maintains medication reconciliation, smoking-relapse prevention, kidney monitoring, and ownership of results without substituting for urologic oncology.

Escalation, referral, and safety net#

Emergency assessment is required for sudden inability to urinate, severe or increasing lower abdominal pain, a rapidly enlarging bladder, heavy bleeding, repeated or large clots, catheter blockage, little or no urine output, fainting, shortness of breath, chest pain, fever with urinary symptoms, confusion, or hypotension. New leg weakness, saddle numbness, loss of bowel control, or rapidly changing gait raises a spinal emergency rather than routine prostate disease.

Same-day specialist coordination is appropriate for retention with kidney injury or hydronephrosis, a difficult or traumatic catheterization, ongoing gross hematuria on anticoagulation, or inability to maintain hydration and monitoring after decompression. A stable appearance does not cancel objective organ risk.

Expedited urology referral is required for visible hematuria, recurrent microscopic hematuria in a risk-based pathway, a suspicious examination or imaging finding, recurrent infection, bladder stones, persistent high residual urine, and symptoms not responding to a coherent first plan. Nephrology referral is added for substantial proteinuria, casts, dysmorphic red cells, persistent kidney dysfunction, or systemic findings suggesting parenchymal disease.

Written instructions distinguish expected mild catheter discomfort from obstruction, infection, and dangerous bleeding. They name the daytime urology contact, after-hours destination, anticoagulation contact, and who will communicate pathology. "Check the portal" is not a safety net.

Communication, shared decisions, and equity#

The clinician explains the split pathway: "Your prostate may be contributing to poor emptying. The blood needs its own evaluation because a prostate finding or a blood thinner cannot tell us where bleeding started. The kidney changes also mean we should protect drainage now rather than wait for a routine visit."

Questions about urination, sexual function, incontinence, and rectal examination are asked privately and with permission. The patient chooses anatomy terms and who may join the discussion. Teach-back checks that he understands why a catheter, an imaging test, and cystoscopy are different decisions.

Shared decisions compare outcomes that matter to him: sleep, travel, and steadiness. They compare sexual and ejaculatory function, catheter burden, and procedure recovery. They compare durability and the risk of another retention event. A long list of technologies is not informed consent. The clinician explains which options fit his anatomy and risks, what evidence is uncertain, and what would trigger a change.

Access planning addresses transportation, distance to urology, and insurance authorization. It addresses catheter supplies, bathroom cleanliness, and hand dexterity. It addresses vision, phone access, and whether he can obtain urgent help while living alone. A professional interpreter and accessible written or audio instructions are used when preferred. A trusted support person may help only with the patient's permission.

Follow-up and contingencies#

The next-day call checks urine flow through the catheter, color, and clots. It checks pain, fever, and dizziness. It checks oral intake and the agreed anticoagulation plan. Kidney function and electrolytes are rechecked on the clinically appropriate schedule. The urology visit confirms catheter strategy, hematuria imaging, cystoscopy, and the person responsible for each result.

A voiding trial occurs only after the drainage and medicine plan is ready, and passing a small amount of urine is not the same as emptying safely, so symptoms and post-void residual are reassessed. Failure leads to continued safe drainage and a plan to distinguish persistent outlet obstruction from poor bladder contraction. Repeated blind trials without ownership add harm.

At four to six weeks, or sooner if the pathway requires, the primary-care team reviews symptom score, sleep, standing blood pressure, falls, sexual effects, residual volume, kidney function, medication adherence, and catheter status. The cataract surgeon has the medicine history. Prostate-marker decisions are revisited after acute retention and instrumentation no longer confound interpretation.

Three contingencies remain explicit:

• Kidney function normalizes and emptying improves: Continue a monitored symptom plan while completing hematuria evaluation and discussing long-term outlet management.
• Residual urine stays high despite symptom improvement: Do not let a better stream substitute for bladder and kidney measurements. Reassess obstruction, detrusor function, and procedural options.
• Hematuria testing is initially negative: Confirm that the complete risk-appropriate pathway was performed, document recurrence instructions, and use urology guidance for repeat assessment rather than declaring lifetime clearance.

Pathology communication is closed-loop. The team records when the result was reviewed, who spoke with the patient, what remains uncertain, the next appointment, and what happens if the appointment cannot be kept.

Reasoning traps and alternative pathways#

• Calling every older man's urinary symptoms BPH: Lower urinary tract symptoms arise from the bladder, outlet, nerves, medicines, sleep, fluid distribution, and systemic disease.
• Attributing hematuria to anticoagulation: A medicine can intensify blood loss without identifying a benign source.
• Treating a symptom score as a diagnosis: The score measures burden and response, not anatomy, obstruction, or cancer risk.
• Using one residual cutoff as certainty: Timing, technique, bladder capacity, repeated values, kidney findings, and symptoms shape the meaning.
• Starting a bladder-relaxing medicine before checking emptying: Storage symptoms and retention can coexist. A treatment for urgency may worsen an unsafe residual.
• Giving antibiotics without evidence of infection: This can cause adverse effects, resistance, and delay in stone, tumor, or obstruction evaluation.
• Ordering imaging but omitting cystoscopy: Upper-tract imaging and direct bladder inspection have overlapping but nonidentical roles.
• Using a normal prostate examination as reassurance: Many urinary tract tumors and significant obstruction are not excluded by rectal examination.
• Stopping anticoagulation reflexively: Bleeding and embolic risks must be balanced for the actual procedure and patient.
• Losing ownership after referral: A placed referral does not confirm drainage, imaging, cystoscopy, pathology, or treatment.

An alternative infectious pathway would emerge with fever, pyuria, positive culture, and prostate or flank tenderness, and colicky pain with a ureteral stone would shift imaging and analgesia while hematuria follow-up remained proportional. Proteinuria, casts, edema, and persistent kidney dysfunction would add nephrology. New saddle sensory loss and bilateral weakness would trigger emergency spinal imaging. Sudden painful retention would require immediate decompression rather than the monitored ambulatory coordination used here.

Evidence limits and what could change#

The 2026 AUA lower urinary tract guideline is current at drafting and emphasizes history, examination, and symptom measurement. It also emphasizes urinalysis, shared decisions, and therapy-specific adverse effects. Its evidence base does not make symptoms synonymous with benign prostate obstruction. Local procedure availability, anatomy, frailty, and preferences still change the choice.

The 2025 AUA and SUFU update addresses microscopic hematuria, while the patient in this analysis reported visible blood. ACR guidance and other reviews support a more complete evaluation for gross hematuria, but imaging recommendations differ across organizations. Radiation, contrast, and false positives must be balanced. So must incidental findings, access, and missed-lesion risk. No urine marker eliminates every need for direct evaluation.

Post-void residual volume is useful but not self-interpreting. The relation between a specific residual and future bladder or kidney harm varies with duration, pressure, and infections. It varies with hydronephrosis, renal function, and bladder contractility. The creatinine change described in this analysis and bilateral dilation justify a more urgent drainage pathway than symptoms alone would.

This case deliberately reveals both outlet obstruction and a bladder tumor. Another person could have isolated prostate enlargement, a stone, or infection. Another could have glomerular disease, urethral stricture, underactive bladder, or no identified malignancy after complete evaluation. This moderate-risk case has completed human review by Jasaman (Jasmin) Tojjar, MD, PhD.

Key points#

• New visible hematuria needs its own evaluation even when prostate enlargement, anticoagulation, or infection seems plausible.
• Repeated residual urine, kidney function, and upper-tract findings determine bladder-safety urgency more reliably than symptom severity alone.
• Urinalysis, culture, imaging, cystoscopy, and bladder-function tests answer different questions and should be ordered only when their result changes a decision.
• Medicines for lower urinary tract symptoms require explicit checks for orthostasis, falls, sexual effects, eye surgery, kidney function, interactions, and retention.
• Safe longitudinal care assigns ownership for drainage, repeat measurements, hematuria results, pathology, anticoagulation, and return thresholds.